SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.

Otros idiomas Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Acciones

688266

CNE100003RP1

Precio de cierre Shanghai S.E. Otros sitios de cotización 00:00:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
54,22 ^CNY	-2,06 %		-4,53 %	+2,42 %

19/04	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
23/02	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	12/04
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin	08/12
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results	19/09/23
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index	18/09/23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug	31/07/23
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	13/06/23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/04/23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding	21/04/23
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug	19/04/23
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug	11/04/23
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China	03/03/23
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	13/10/22
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/08/22
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment	17/08/22
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index	10/06/22
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Acciones

688266

CNE100003RP1

Otros idiomas

Filtros